PF 5212371
Alternative Names: AGG-523; PF-05212371; PF-5212371; WAY-266523Latest Information Update: 04 Mar 2011
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Anti-inflammatories
- Mechanism of Action Aggrecanase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 28 Feb 2011 Discontinued - Phase-I for Osteoarthritis in Japan (PO)
- 28 Feb 2011 Discontinued - Phase-I for Osteoarthritis in USA (PO)
- 15 Oct 2009 Wyeth has been acquired by Pfizer